USCAREPHARM Selected as a ‘2026 Global IP Star Company,’ Accelerating Its Global Market Expansion
Writer USCarePharm
2026-04-22
[BioTimes] USCAREPHARM Co., Ltd. (CEO Seokjin Song), a company specializing in bio-medical aesthetics, announced on the 17th that it has been finally selected as a 2026 Global IP (Intellectual Property) Star Company, a program organized by the Korean Intellectual Property Office and Gyeonggi Province.
The Global IP Star Company program selects promising small and medium-sized enterprises with strong export growth potential and provides them with customized, comprehensive intellectual property-based support over a three-year period. USCAREPHARM was selected in recognition of its technological capabilities in biodegradable polymer-based medical devices and the global expansion potential of its proprietary brands.
USCAREPHARM is an R&D-driven company that has developed differentiated products in the fields of medical aesthetics and bio-healthcare based on its experience in pharmaceutical and healthcare research and development. Leveraging its accumulated core technologies, including ORTE® biodegradable microparticle technology and its development experience with Curing Hyaluronic Acid®, a solid cross-linked hyaluronic acid material, the company has continued to commercialize and market its technologies through its medical aesthetics brand ERBELLA®.
Recently, USCAREPHARM has achieved tangible results in overseas markets such as Vietnam and Saudi Arabia, while also stepping up its entry into the South American market, further accelerating its global business expansion. Through this latest selection, the company plans to strengthen its IP competitiveness by further accelerating overseas patent filings and securing trademark and design rights.
As a result of this selection, USCAREPHARM will receive intensive support over the next three years for securing intellectual property rights, including overseas patent applications and brand and design development. Based on this support, the company plans to strengthen its technological protection barriers as it expands into global aesthetics markets such as North America and Europe.
A representative from USCAREPHARM stated, “Being selected as a Global IP Star Company is a meaningful achievement that officially recognizes our technological capabilities and global growth potential.” The representative added, “Moving forward, we will build on a strong intellectual property portfolio to grow into an innovative company leading the global bio-medical aesthetics market.”
The Global IP Star Company program selects promising small and medium-sized enterprises with strong export growth potential and provides them with customized, comprehensive intellectual property-based support over a three-year period. USCAREPHARM was selected in recognition of its technological capabilities in biodegradable polymer-based medical devices and the global expansion potential of its proprietary brands.
USCAREPHARM is an R&D-driven company that has developed differentiated products in the fields of medical aesthetics and bio-healthcare based on its experience in pharmaceutical and healthcare research and development. Leveraging its accumulated core technologies, including ORTE® biodegradable microparticle technology and its development experience with Curing Hyaluronic Acid®, a solid cross-linked hyaluronic acid material, the company has continued to commercialize and market its technologies through its medical aesthetics brand ERBELLA®.
Recently, USCAREPHARM has achieved tangible results in overseas markets such as Vietnam and Saudi Arabia, while also stepping up its entry into the South American market, further accelerating its global business expansion. Through this latest selection, the company plans to strengthen its IP competitiveness by further accelerating overseas patent filings and securing trademark and design rights.
As a result of this selection, USCAREPHARM will receive intensive support over the next three years for securing intellectual property rights, including overseas patent applications and brand and design development. Based on this support, the company plans to strengthen its technological protection barriers as it expands into global aesthetics markets such as North America and Europe.
A representative from USCAREPHARM stated, “Being selected as a Global IP Star Company is a meaningful achievement that officially recognizes our technological capabilities and global growth potential.” The representative added, “Moving forward, we will build on a strong intellectual property portfolio to grow into an innovative company leading the global bio-medical aesthetics market.”
관련자료
-
링크
-
Next